Eli Lilly’s ongoing technology evaluation agreement with Peptron, limited to internal R&D testing of the SmartDepot microsphere platform for sustained-release peptide formulations including GLP-1 agonists, expires on October 7 without any confirmed transition to a binding commercial license or technology transfer. Recent reports confirm continued in-vivo studies and expanded CNS research but note no announcements of upfront payments, milestone structures, or exclusive rights that would resolve the market to Yes. Lilly’s separate partnerships, such as with Camurus for FluidCrystal long-acting injectables, further signal diversified delivery strategies. With under three weeks remaining and the agreement explicitly non-binding for commercialization, traders see limited scope for a sudden deal.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% шанс
$11,414 Обс.
$11,414 Обс.
Oct 7, 2026
13% шанс
$11,414 Обс.
$11,414 Обс.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, limited to internal R&D testing of the SmartDepot microsphere platform for sustained-release peptide formulations including GLP-1 agonists, expires on October 7 without any confirmed transition to a binding commercial license or technology transfer. Recent reports confirm continued in-vivo studies and expanded CNS research but note no announcements of upfront payments, milestone structures, or exclusive rights that would resolve the market to Yes. Lilly’s separate partnerships, such as with Camurus for FluidCrystal long-acting injectables, further signal diversified delivery strategies. With under three weeks remaining and the agreement explicitly non-binding for commercialization, traders see limited scope for a sudden deal.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Ринок відкрито: May 5, 2026, 8:02 PM ET
Обсяг
$11,414Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETВирішувач
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, limited to internal R&D testing of the SmartDepot microsphere platform for sustained-release peptide formulations including GLP-1 agonists, expires on October 7 without any confirmed transition to a binding commercial license or technology transfer. Recent reports confirm continued in-vivo studies and expanded CNS research but note no announcements of upfront payments, milestone structures, or exclusive rights that would resolve the market to Yes. Lilly’s separate partnerships, such as with Camurus for FluidCrystal long-acting injectables, further signal diversified delivery strategies. With under three weeks remaining and the agreement explicitly non-binding for commercialization, traders see limited scope for a sudden deal.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Обсяг
$11,414Дата завершення
Oct 7, 2026Ринок відкрито
May 5, 2026, 8:02 PM ETВирішувач
0x65070BE91...Eli Lilly’s ongoing technology evaluation agreement with Peptron, limited to internal R&D testing of the SmartDepot microsphere platform for sustained-release peptide formulations including GLP-1 agonists, expires on October 7 without any confirmed transition to a binding commercial license or technology transfer. Recent reports confirm continued in-vivo studies and expanded CNS research but note no announcements of upfront payments, milestone structures, or exclusive rights that would resolve the market to Yes. Lilly’s separate partnerships, such as with Camurus for FluidCrystal long-acting injectables, further signal diversified delivery strategies. With under three weeks remaining and the agreement explicitly non-binding for commercialization, traders see limited scope for a sudden deal.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання